Researcher Spotlight: Nathan Ungerleider, PhD Tulane University School of Medicine The Epstein-Barr virus (EBV) has been shown to be linked to the development of Burkitt lymphoma, an aggressive B-cell lymphoma. EBV-infected cells are particularly efficient, capable of altering normal cells…
Researcher Spotlight: Irene Scarfo, PhD Massachussetts General Hospital The majority of chimeric antigen receptor (CAR) T-cell therapies currently being tested in lymphoma, including both therapies that have received U.S. Food and Drug Administration (FDA) approval, target CD19 antigen, and rely…
Researcher Spotlight: Teresa Sadras, PhD Beckman Research Institute City of Hope Though chronic lymphocytic leukemia (CLL) patients with indolent (slow-growing) forms of the disease have a high rates of long-term survival, patients with more aggressive forms of CLL have significantly…
Researcher Spotlight: Antonia Rotolo, MD, PhD University of Pennsylvania Perelman School of Medicine Researchers are seeking ways to expand the effectiveness of chimeric antigen receptor (CAR) T-cell therapy to lymphoma subtypes for whom the most common type of CAR therapy,…
Researcher Spotlight: Lena Lupey-Green, PhD Penn State College of Medicine Lymphomas that are associated with infection of the Epstein-Barr virus (EBV), which induces a chronic, latent infection in B-cells, present a unique therapeutic opportunity wherein the virus can be specifically…
Researcher Spotlight: Yuxuan Liu, PhD Columbia University Medical Center Recent research has shown that genes encoding histone acetyltransferase (HAT) enzymes, EP300 and CREBBP, often become mutated in the malignant cells of follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL).…
Researcher Spotlight: Elise A. Chong, MD University of Pennsylvania Perelman School of Medicine Chimeric antigen receptor (CAR) T-cell therapy has been an effective treatment for any patients with B-cell lymphomas who don’t respond to other therapies, producing remissions in 30…
Researcher Spotlight: Jianguo Tao, MD, PhD H. Lee Moffitt Cancer Center With the success of ibrutinib in mantle cell lymphoma (MCL) and other B-cell lymphomas, researchers have become focused on the problem of treatment resistance – not only do a…
Researcher Spotlight: Sandeep Dave, MD, MS Duke University Medical Center “Even as progress has been made in a number of cancers, the options for MCL patients remain disappointingly narrow,” says Dr. Dave. He and his colleagues are seeking to expand…
Researcher Spotlight: Owen A. O’Connor, MD, PhD Columbia University Medical Center A long-time member of the Lymphoma Research Foundation’s Scientific Advisory Board , and a founding Executive Committee member of LRF’s Mantle Cell Lymphoma Consortium, Dr. Owen O’Connor has been…